Harbour Antibodies BV and Harbour Antibodies HCAb BV v. Leveragen, Inc., No. 1:26-cv-15082 (D. Mass.), is a patent complaint filed November 12, 2026. The complaint says Harbour Antibodies BV is a Dutch company and Harbour Antibodies HCAb BV is a Dutch corporation, each with a place of business in Rotterdam, Netherlands, and that Harbour Antibodies HCAb BV is a "fully owned subsidiary" of Harbour Antibodies BV. It says Leveragen, Inc. is a Delaware corporation with a place of business in Woburn, Massachusetts, and describes it as a biotech company specializing in genetic engineering. The complaint demands a jury trial.
The patents
The complaint asserts U.S. Patent 8,921,522, Binding Molecules, issued December 30, 2014, as corrected by a certificate of correction dated January 8, 2019; U.S. Patent 8,921,524, Binding Molecules, issued December 30, 2014, as corrected by a certificate of correction dated May 7, 2019; U.S. Patent 9,346,877, Binding Molecules, issued May 24, 2016; U.S. Patent 9,353,179, Binding Molecules, issued May 31, 2016; and U.S. Patent 9,365,655, Soluble heavy-chain only antibodies, issued June 14, 2016. It alleges that the plaintiffs own the entire right, title, and interest in the five patents, confirmed by assignments recorded in the USPTO.
The complaint says the plaintiffs produce heavy chain-only antibodies in transgenic rodents, including mice, which it calls the HCAb Platform and Harbour Mice, and that the platform has been licensed more than 40 times to pharmaceutical and biotechnology companies, including a Massachusetts company, and to academic institutions.
The accused platform
The complaint says Leveragen sells and offers for sale a platform, the SSM platform, for generating single-domain antibodies, advertised on Leveragen's website as NANOBODIES, and that the platform includes a Singularity Sapiens Mouse that, according to Leveragen's materials, generates heavy chain antibodies from the complete human VH repertoire integrated into the mouse Igh locus. It also points to two Leveragen PCT applications, filed in 2022 and 2023, and to a figure in one of them that it says shows the platform's mice. The complaint alleges, on information and belief, that the platform includes one or more mice designated SSV1 through SSV6 whose VH, D, and J sequences correspond to the gene segments disclosed and claimed in the patents.
The complaint alleges, on information and belief, that use of the SSM platform to generate heavy chain-only antibodies practices at least claim 1 of the '522, '524, '877, and '179 patents, and that use of at least the SSV1 mouse meets at least claim 1 of the '655 patent, literally or under the doctrine of equivalents. It also alleges, on information and belief, that Leveragen induces its customers to infringe through its instructions, guidance, advertising, and promotion of the platform.
The counts and the prayer
Counts I, II, IV, VI, and VII allege, on information and belief, direct infringement under 35 U.S.C. § 271(a) and induced infringement under § 271(b) of the '522, '524, '877, '179, and '655 patents, respectively, and allege, on information and belief, that the infringement is willful. Counts III and V seek judicial correction of what the complaint calls an "evident error" in claim 1 of the '877 patent and claim 1 of the '179 patent: each claim recites "a functional CH1 domain with an antigen," and the complaint asks the court to correct the phrase to mean "a functional CH1 domain." Count VIII alleges unfair methods of competition or unfair or deceptive acts or practices under Massachusetts General Laws chapter 93A.
The prayer asks the court to judicially correct the two claim phrases; to enter judgment that Leveragen has infringed the five patents, directly and indirectly, and that the infringement is willful; to permanently enjoin infringement of the '522, '524, and '655 patents; and to award damages, including treble damages for willful infringement, costs and attorneys' fees under 35 U.S.C. § 285, chapter 93A damages trebled under § 11 with attorneys' fees, preliminary and permanent injunctive relief under chapter 93A, all applicable damages, including exemplary, compensatory, punitive, statutory, and treble damages or disgorgement of profits, interest, and other relief.
Notice and the earlier suits
The complaint alleges, on information and belief, that Leveragen has been aware of the plaintiffs' platform and the patents since at least July 18, 2025, and says that on that date Harbour Antibodies sent Leveragen an email identifying several patents and raising concerns about Leveragen's business. It says the plaintiffs filed an earlier complaint against Leveragen in the same court on October 14, 2025, Harbour Antibodies BV v. Leveragen, Inc., No. 1:25-cv-13004, asserting all of the patents in this suit and a sixth patent, which gave Leveragen further notice, and that the plaintiffs dismissed that complaint without prejudice on November 19, 2025.
Harbour Antibodies BV and Harbour Antibodies HCAb BV also asserted the '877 and '179 patents, together with other plaintiffs and two other patents, in a suit against another company filed December 23, 2021, in the District of Delaware, No. 1:21-cv-01807.
Jurisdiction and venue
The complaint pleads subject matter jurisdiction under 28 U.S.C. §§ 1331 and 1338(a) and (b), supplemental jurisdiction over the Massachusetts claim under 28 U.S.C. § 1367(a), and venue under 28 U.S.C. §§ 1391(b), 1391(c), and 1400(b).
What to watch next
Watch for Leveragen's response to the complaint, including any response to the judicial-correction counts. The case can end at any time, including by settlement or voluntary dismissal.